Classification systems for acute and chronic leukaemias

被引:38
作者
Szczepanski, T
van der Velden, VHJ
van Dongen, JJM
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands
[2] L Warynski Silesian Med Acad, Dept Paediat Haematol & Oncol, Zabrze, Poland
关键词
haematopoietic malignancies; acute lymphoblastic leukaemia (ALL); acute myeloid leukaemia (AML); chronic myeloid leukaemia (CML); chronic lymphocytic leukaemia (CLL); non-Hodgkin's lymphoma (NHL); immunophenotyping; flow cytometry; immunoglobulin (lg); T-cell receptor (TCR); somatic mutations; chromosome translocations; fusion genes; gene expression profiles;
D O I
10.1053/ybeha.2003.285
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Modern classification systems for acute and chronic leukaemias are based on cytomorphology, cytochemistry, immunophenotyping, immunogenetics and molecular cytogenetics. Morphology forms the initial diagnosis of leukaemia, but generally is not sufficient to identify biologically and clinically relevant subsets within the main categories of leukaemia. Immunophenotyping precisely defines the lineage and stage of differentiation of malignantly transformed haematopoietic cells. This is usually sufficient for precise classification of mature lymphoid malignancies, although immunogenetic and (molecular) cytogenetic studies might be helpful to confirm the diagnosis of disseminated non-Hodgkin's lymphomas. However, certain categories of disease that are clearly defined by cytomorphology and immunophenotyping, particularly acute leukaemias, are still heterogeneous, mainly owing to different underlying leukaemogenic events. Immunophenotyping can reveal subgroups highly suggestive of certain chromosome aberrations but reliable identification of such aberrations requires cytogenetic or molecular studies. Such combined diagnostic information forms the basis of current WHO classification of tumours of haematopoietic and lymphoid tissues. This will be complemented in the near future with novel criteria revealed by microarray gene expression profiling. This chapter summarizes and comments on the currently used immunophenotypic classification systems of acute and chronic leukaemias and on the added value of molecular diagnostics.
引用
收藏
页码:561 / 582
页数:22
相关论文
共 108 条
[31]  
DETOTERO D, 1993, BLOOD, V82, P528
[32]  
DREXLER HG, 1987, LEUKEMIA, V1, P697
[33]   Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML) [J].
Falini, B ;
Flenghi, L ;
Fagioli, M ;
LoCoco, F ;
Cordone, I ;
Diverio, D ;
Pasqualucci, L ;
Biondi, A ;
Riganelli, D ;
Orleth, A ;
Liso, A ;
Martelli, MF ;
Pelicci, PG ;
Pileri, S .
BLOOD, 1997, 90 (10) :4046-4053
[34]   Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia [J].
Ferrando, AA ;
Neuberg, DS ;
Staunton, J ;
Loh, ML ;
Huard, C ;
Raimondi, SC ;
Behm, FG ;
Pui, CH ;
Downing, JR ;
Gilliland, DG ;
Lander, ES ;
Golub, TR ;
Look, AT .
CANCER CELL, 2002, 1 (01) :75-87
[35]   Clinical and biologic features of CD4+CD56+ malignancies [J].
Feuillard, J ;
Jacob, MC ;
Valensi, F ;
Maynadié, M ;
Gressin, R ;
Chaperot, L ;
Arnoulet, C ;
Brignole-Baudouin, F ;
Drénou, B ;
Duchayne, E ;
Falkenrodt, A ;
Garand, R ;
Homolle, E ;
Husson, B ;
Kuhlein, E ;
Le Calvez, G ;
Sainty, D ;
Sotto, MF ;
Trimoreau, F ;
Béné, MC .
BLOOD, 2002, 99 (05) :1556-1563
[36]  
FOON KA, 1986, BLOOD, V68, P1
[37]  
GEISLER CH, 1991, BLOOD, V78, P1795
[38]  
GRIFFIN JD, 1983, BLOOD, V62, P557
[39]   Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas [J].
Haedicke, W ;
Chott, A ;
Moretta, L ;
Rüdiger, T ;
Ott, G ;
Müller-Hermelink, HK .
BLOOD, 2000, 95 (11) :3628-3630
[40]  
HAGEMEIJER A, 1987, LEUKEMIA, V1, P24